

Perspective of Radiation Use for Patients, Brachytherapy in the Global Oncological Landscape

Bernadette Acela*

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA

Introduction

Brachytherapy is a type of radiation in which radioactive materials are precisely placed directly into or close to the tumour. This treatment is recommended for cancer patients of various sorts. Physicians from a variety of disciplines may be involved in referring patients to brachytherapy or performing the procedure. Based on the high evidence from randomised controlled trials, brachytherapy is primarily indicated: 1) in treatment of metastatic cervical cancer in combination with chemo radiation; 2) in surgically treated patients with uterine endometrial cancer to reduce the risk of vaginal vault recurrence; 3) in patients with high-risk prostate cancer to perform dose escalation and improve progression-free survival; and 4) in patients with breast cancer to perform dose escalation and improve advancement survival [1].

Brachytherapy is a type of cancer treatment that uses a specific type of radiation therapy. It entails inserting sealed radioactive substances into or around the tumour to be treated, either directly or through catheters. In the context of radiation use for patients, brachytherapy stays an optimal technique, and referral to or installation of brachytherapy can involve a wide range of medical specialisations. Brachytherapy has established the gold standard of care as a single modality or as a boost following External-Beam Radiotherapy (EBRT) for malignancies that require a high dose of radiation to be treated since the mid-twentieth century [2].

Patients' Radiation Use and Brachytherapy

Treatment Approaches: Radiation therapy is used to treat three types of cancers: 1) curative, definitive radiotherapy (with or without chemotherapy); 2) adjuvant treatment to reduce the risk of local relapse following surgery; and 3) palliative treatment of symptomatic tumours. The deoxyribonucleic acid (DNA) chain is the main target of therapeutic irradiation, and if not repaired, radiation-induced DNA damage causes immediate apoptosis, cell cycle rearrangement, and alterations in the microenvironment. The irradiation in EBRT procedures, which are the most frequent, comes from beams generated outside the patient. Intensity-modulated radiotherapy (IMRT), stereotactic radiotherapy, and proton therapy are examples of modern EBRT techniques [3]. All of these methods were created in order to enhance the balance of tumour to healthy tissue dosage. Sometimes in cases, organ experts such as urologists and gynaecologic surgeons may be required for the accurate perioperative placement of brachytherapy catheters. This multidisciplinary approach is especially important for perioperative procedures where the target volume is difficult to reach without endoscopic guidance (e.g., oesophageal or endobronchial malignancies) or when the target volume is adjacent to particularly sensitive organs [4].

Advantages of the Approach: The intense radiation dose administered directly to the tumour, nearby to the sources, ensures brachytherapy's efficacy. When compared to standard external-beam procedures, brachytherapy offers

*Address for Correspondence: Bernadette Acella, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA, E-mail: bernadetteacella@ccf.org

Copyright: © 2021 Acella, B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received 02 November 2021; **Accepted** 16 November 2021; **Published** 23 November 2021

dosimetry advantages with very sharp radiation dose variations. When compared to lengthy fractionated radiation schemes, treatment can be administered in a matter of days, which is therapeutically useful in proliferating tumours to reduce overall healing time and hence improve local control by restricting tumour reproduction. In chronic primary tumours requiring high doses to be cured, such as cervical cancer or prostate cancer, brachytherapy can be used alone or in combination with EBRT to enhance the dose focally [5].

Study Improving the Therapeutic Index through Brachytherapy: According to international guidelines, external radiotherapy combined with concurrent chemotherapy is the standard treatment for patients with locally advanced cervical cancer (LACC). In that study, the 5-year disease-free life expectancy was 69.3 percent in the neoadjuvant chemotherapy plus surgery group compared to 76.7 percent in the concurrent chemo radiation plus radiotherapy treatment group.

Breast cancer is a type of cancer that affects: In some patients with breast cancer, Accelerated Partial Breast Irradiation (APBI) is an appealing adjuvant treatment option. It comprises of putting no permanent sources within the tumour site to reduce the risk of local relapse by delivering focused irradiation to treat only the lumpectomy bed plus a safety margin after breast-conserving surgery as a perioperative or postoperative treatment.

Conclusion

In several clinical situations, brachytherapy is indicated as a sole treatment or in combination with other treatment modalities (external radiotherapy or surgery), with strong evidence that it has a position in the global oncological environment. Physicians from a variety of specialities are engaged in the brachytherapy procedure, including patient referral, brachytherapy installation, and post-treatment management.

Reference

1. Skowronek, Janusz. "Current status of brachytherapy in cancer treatment—short overview". *J Contemp Brachytherapy* 9 (2017): 581-589.
2. Han, Kathy., Michael Milosevic, Anthony Fyles, and Melania Pintilie, et al. "Trends in the utilization of brachytherapy in cervical cancer in the United States". *Int J Radiat Oncol Biol Phys* 87 (2013): 111-119.
3. Gill, Beant S., Jeff F Lin, Thomas C Krivak, and Paniti Sukumvanich, et al. "National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements". *Int J Radiat Oncol Biol Phys* 90 (2014): 1083-1090.
4. Hoskin, Peter J., Ana M Rojas, Peter J Bownes, and Gerry J Lowe, et al. "Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer". *Radiother Oncol* 103 (2012): 217- 222.
5. Potter, Richard., Johannes Dimopoulos, Petra Georg, and Stefan Lang, et al. "Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer". *Radiother Oncol* 83 (2007): 148-155.

How to cite this article: Acella, Bernadette. "Perspective of Radiation Use for Patients, Brachytherapy in the Global Oncological Landscape". *J Oncol Med & Pract* 6 (2021): 144.